Table 4 Distribution of treatments received and progression of dieses between both groups
Treatment | C3GN (n = 10) | C3 Controls (n = 21) | p value |
|---|---|---|---|
aRAS blockers (%) | 70 (n = 7) | 85 (n = 18) | 0.3 |
Steroids (%) | 30 (n = 3) | 72 (n = 15) | 0.05 |
bMMF (%) | 20 (n = 2) | 33 (n = 7) | 0.4 |
cTac (%) | 0 | 10 (n = 2) | 1 |
dCP (%) | 10 (n = 1) | 14 (n = 3) | 1 |
eCsA (%) | 0 | 19 (n = 4) | 0.3 |
fAZA (%) | 0 | 10 (n = 2) | 1 |
No immunosuppression (%) | 40 (n = 4) | 28 (n = 6) | 0.7 |
Missing data (%) | 20 (n = 2) | 0 | 0.09 |
Immunosuppression (%) | 40 (n = 4) | 72 (n = 15) | 0.4 |
Median Duration of immunosuppression (days) | 263 (IQR 126–629) | 302 (IQR 184–1496) | 0.5 |